ACM
SAGE

Atika Capital Management’s Sage Therapeutics SAGE Stock Holding History

Atika Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-52,500
Closed -$8.35M – 90
2019
Q1 		$8.35M Buy
+52,500
New +$7.6M 1.7% 19
2017
Q4 		– Sell
-15,000
Closed -$935K – 77
2017
Q3 		$935K Buy
+15,000
New +$1.18M 0.27% 72

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Atika Capital Management's SAGE Position: Q3 2019 in Review

Atika Capital Management sold out of Sage Therapeutics (SAGE) in Q3 2019, closing a stake of 38,500 shares — an estimated $7.05M sold.

Atika Capital Management first reported a position in SAGE in Q2 2015 and held it in 7 quarters. The position peaked at $7.05M in Q2 2019. 285 funds tracked by Wall St. Rank hold SAGE as of Q3 2019.

  • Atika Capital Management reported no remaining Sage Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Atika Capital Management sold 38,500 Sage Therapeutics shares in Q3 2019, an estimated $7.05M.
  • Atika Capital Management first reported a position in Sage Therapeutics in Q2 2015 and held it in 7 quarters.
  • Atika Capital Management's Sage Therapeutics position peaked at $7.05M in Q2 2019.
  • 285 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2019.

Based on Atika Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.